Torque Teno Virus Load-Inverse Association with Antibody-Mediated Rejection after Kidney Transplantation

Transplantation

Volumn 101, Issue 2, 2017, Pages 360-367

  Schiemann, Martin ^a   Puchhammer Stöckl, Elisabeth ^a   Eskandary, Farsad ^a   Kohlbeck, Philip ^a   Rasoul Rockenschaub, Susanne ^a   Heilos, Andreas ^a   Kozakowski, Nicolas ^a   Görzer, Irene ^a   Kikić, Željko ^a   Herkner, Harald ^a   Böhmig, Georg A ^a   Bond, Gregor ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BELATACEPT; CYCLOSPORIN; DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; ALLOANTIBODY; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; VIRUS DNA;

ADULT; ANTIBODY MEDIATED REJECTION; ANTIBODY RESPONSE; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RISK ASSESSMENT; RISK FACTOR; TORQUE TENO VIRUS 1; VIRUS LOAD; ADVERSE EFFECTS; BIOPSY; BLOOD; CHI SQUARE DISTRIBUTION; GENETICS; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MIDDLE AGED; ODDS RATIO; PATHOGENICITY; PROSPECTIVE STUDY; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

ADULT; BIOMARKERS; BIOPSY; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; GRAFT REJECTION; HUMANS; IMMUNITY, HUMORAL; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TORQUE TENO VIRUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84981717432     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001455     Document Type: Article

References (37)

1. Lamb KE Lodhi S Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Tranplant. 2011; 11: 450-462.
2. Loupy A Hill GS Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012; 8: 348-357.
3. Sellarés J de Freitas DG Mengel M. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Tranplant. 2012; 12: 388-399.
4. Wiebe C Nickerson P. Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Curr Opin Organ Transplant. 2013; 18: 470-477.
5. Haas M Sis B Racusen LC. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Banff meeting report writing committee. Am J Tranplant. 2014; 14 272-283.
6. Cravedi P Heeger PS. Immunologic monitoring in transplantation revisited. Curr Opin Organ Transplant. 2012; 17: 26-32.
7. Chen T Vaisanen E Mattila PS. Antigenic diversity and seroprevalences of Torque teno viruses in children and adults by ORF2-based immunoassays. J Gen Virol. 2013; 94: 409-417.
8. Rocchi J Ricci V Albani M. Torquetenovirus DNA drives proinflammatory cytokines production and secretion by immune cells via toll-like receptor 9. Virology. 2009; 394: 235-242.
9. Okamoto H. History of discoveries and pathogenicity of TT viruses. Curr Top Microbiol Immunol. 2009; 331: 1-20.
10. Burra P Masier A Boldrin C. Torque Teno Virus: any pathological role in liver transplanted patients? Transplant Int. 2008; 21: 972-979.
11. Moen EM Sagedal S Bjøro K. Effect of immune modulation on TT virus (TTV) and TTV-like-mini-virus (TLMV) viremia. J Med Virol. 2003; 70: 177-182.
12. Görzer I Haloschan M Jaksch P. Plasma DNA levels of Torque teno virus and immunosuppression after lung transplantation. J Heart Lung Transplant. 2014; 33: 320-323.
13. Görzer I Jaksch P Kundi M. Pre-transplant plasma Torque Teno virus load and increase dynamics after lung transplantation. PLoS One. 2015; 10: e0122975.
14. De Vlaminck I Khush KK Strehl C. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell. 2013; 155: 1178-1187.
15. Eskandary F Bond G Schwaiger E. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Trials. 2014; 15: 107.
16. Eskandary F Bond G Kozakowski N. Diagnostic contribution of donor-specific antibody characteristics to uncover late silent antibody-mediated rejection-results of a cross-sectional screening study. Transplantation. 2016.
17. Bartel G Wahrmann M Regele H. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Tranplant. 2010; 10: 2033-2042.
18. Schwaiger E Eskandary E Kozakowski N. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection. Nephrol Dial Transplant. 2016; 31: 1342-1351.
19. Levey AS Bosch JP Lewis JB. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Int Med. 1999; 130: 461-470.
20. Maggi F Pifferi M Fornai C. TT virus in the nasal secretions of children with acute respiratory diseases: relations to viremia and disease severity. J Virol. 2003; 77: 2418-2425.
21. Sapir-Pichhadze R Curran SP John R. A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection. Kidney Int. 2015; 87: 182-194.
22. Kikić Ž Kainz A Kozakowski N. Capillary C4d and kidney allograft outcome in relation to morphologic lesions suggestive of antibody-mediated rejection. Clin J Am Soc Nephrol. 2015; 10: 1435-1443.
23. Mizutani K Terasaki P Hamdani E. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Tranplant. 2007; 7: 1027-1031.
24. Béland K Dore-Nguyen M Gagne MJ. Torque Teno virus in children who underwent orthotopic liver transplantation: new insights about a common pathogen. J Infect Dis. 2014; 209: 247-254.
25. Haloschan M Bettesch R Görzer I. TTV DNA plasma load and its association with age, gender, and HCMV IgG serostatus in healthy adults. Age. 2014; 36: 9716.
26. Brassard J Gagné MJ Leblanc D. Association of age and gender with Torque teno virus detection in stools from diarrheic and non-diarrheic people. J Clin Virol. 2015; 72: 55-59.
27. Pera A Campos C López N. Immunosenescence: implications for response to infection and vaccination in older people. Maturitas. 2015; 82: 50-55.
28. Sakiani S Olsen NJ Kovacs WJ. Gonadal steroids and humoral immunity. Nat Rev Endocrinol. 2013; 9: 56-62.
29. Hässig A Roos M Etter A. Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor. Transplant Infect Dis. 2014; 16: 44-54.
30. Han Lee ED Kemball CC Wang J. A mouse model for polyomavirus-associated nephropathy of kidney transplants. Am J Tranplant. 2006; 6: 913-922.
31. Ekberg H Tedesco-Silva H Demirbas A. Reduced exposure to calcineurin inhibitors in renal transplantation. ELITE-Symphony Study. N Engl J Med. 2007; 357: 2562-2575.
32. Lim WH Eris J Kanellis J. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am J Tranplant. 2014; 14: 2106-2119.
33. Liefeldt L Brakemeier S Glander P. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Tranplant. 2012; 12: 1192-1198.
34. Nashan B Gaston R Emery V. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation. 2012; 93: 1075-1085.
35. Poglitsch M Weichhart T Hecking M. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am J Tranplant. 2012; 12: 1458-1468.
36. Vincenti F Rostaing L Grinyo J. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016; 374: 333-343.
37. Christensen JE Christensen JP Kristensen NN. Role of CD28 co-stimulation in generation and maintenance of virus-specific T cells. Int Immunol. 2002; 14: 701-711.